[1] Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y. Current progress of China's free ART program. Cell Res 2005;15(11 − 12):877 − 82. http://dx.doi.org/10.1038/sj.cr.7290362CrossRef
[2] Dou ZH, Zhang FJ, Zhao Y, Jin CR, Zhao DC, Gan XM, et al. Progress on China’s national free antiretroviral therapy strategy in 2002-2014. Chin J Epidemiol 2015;36(12):1345 − 50. http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2015.12.005 (In Chinese). CrossRef
[3] Zhao Y, Han MJ, Ma Y, Li DM. Preplanned Studies: progress towards the 90-90-90 targets for controlling HIV—China, 2018. China CDC Wkly 2019;1(1):5 − 7. http://dx.doi.org/10.46234/ccdcw2019.003CrossRef
[4] Zuo LL, Liu K, Liu HL, Hu YH, Zhang ZJ, Qin JR, et al. Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001–2017). EClinicalMedicine 2020;18:100238. http://dx.doi.org/10.1016/j.eclinm.2019.100238CrossRef
[5] Bayu B, Tariku A, Bulti AB, Habitu YA, Derso T, Teshome DF. Determinants of virological failure among patients on highly active antiretroviral therapy in University of Gondar Referral Hospital, Northwest Ethiopia: a case–control study. HIV/AIDS Res Palliat Care 2017;9:153 − 9. http://dx.doi.org/10.2147/HIV.S139516CrossRef
[6] Zuo ZB, Liang S, Sun XG, Bussell S, Yan J, Kan W, et al. Drug resistance and virological failure among HIV-infected patients after a decade of antiretroviral treatment expansion in eight provinces of China. PLoS One 2016;11(12):e0166661. http://dx.doi.org/10.1371/journal.pone.0166661CrossRef
[7] Zhang JH, Li HL, Shi HB, Jiang HB, Hong H, Dong HJ. Survival analysis of HIV/AIDS patients with access to highly antiretroviral therapy in Ningbo during 2004-2015. Chin J Epidemiol 2016;37(9):1262 − 7. http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2016.09.016 (In Chinese). CrossRef
[8] Manual of the national free antiretroviral treatment. 4th ed. Beijing: People’s Medical Publishing House.
[9] Kan W, Teng T, Liang SJ, Ma YL, Tang H, Zuohela T, et al. Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008–2012: a prospective cohort study. BMJ Open 2017;7(9):e016012. http://dx.doi.org/10.1136/bmjopen-2017-016012CrossRef
[10] Liu PT, Liao LJ, Xu W, Yan J, Zuo ZB, Leng XB, et al. Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015. Medicine (Baltimore) 2018;97(50):e13555. http://dx.doi.org/10.1097/MD.0000000000013555CrossRef